GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
GO:00346613 | Esophagus | ESCC | ncRNA catabolic process | 33/8552 | 43/18723 | 3.25e-05 | 2.69e-04 | 33 |
GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
GO:00346556 | Liver | NAFLD | nucleobase-containing compound catabolic process | 80/1882 | 407/18723 | 3.07e-09 | 4.61e-07 | 80 |
GO:00064016 | Liver | NAFLD | RNA catabolic process | 61/1882 | 278/18723 | 3.26e-09 | 4.76e-07 | 61 |
GO:00083807 | Liver | NAFLD | RNA splicing | 70/1882 | 434/18723 | 4.62e-05 | 1.10e-03 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZCCHC8 | SNV | Missense_Mutation | novel | c.370N>C | p.Glu124Gln | p.E124Q | Q6NZY4 | protein_coding | deleterious(0.03) | benign(0.283) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
ZCCHC8 | SNV | Missense_Mutation | novel | c.1408N>T | p.Pro470Ser | p.P470S | Q6NZY4 | protein_coding | deleterious(0.02) | possibly_damaging(0.82) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZCCHC8 | SNV | Missense_Mutation | novel | c.109N>A | p.Asp37Asn | p.D37N | Q6NZY4 | protein_coding | deleterious(0.02) | benign(0.107) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ZCCHC8 | SNV | Missense_Mutation | | c.775N>G | p.Met259Val | p.M259V | Q6NZY4 | protein_coding | deleterious(0.03) | benign(0.058) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
ZCCHC8 | SNV | Missense_Mutation | | c.2038N>A | p.Glu680Lys | p.E680K | Q6NZY4 | protein_coding | deleterious(0) | possibly_damaging(0.738) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ZCCHC8 | SNV | Missense_Mutation | novel | c.1514N>A | p.Thr505Lys | p.T505K | Q6NZY4 | protein_coding | tolerated(0.93) | benign(0.01) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
ZCCHC8 | SNV | Missense_Mutation | | c.1022N>A | p.Gly341Asp | p.G341D | Q6NZY4 | protein_coding | tolerated(0.7) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZCCHC8 | SNV | Missense_Mutation | | c.595N>A | p.Glu199Lys | p.E199K | Q6NZY4 | protein_coding | deleterious(0) | benign(0.141) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ZCCHC8 | SNV | Missense_Mutation | | c.672G>T | p.Arg224Ser | p.R224S | Q6NZY4 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZCCHC8 | SNV | Missense_Mutation | | c.1214N>G | p.Ser405Cys | p.S405C | Q6NZY4 | protein_coding | deleterious(0) | possibly_damaging(0.707) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |